Hershow Ronald C, O'Driscoll Peter T, Handelsman Ed, Pitt Jane, Hillyer George, Serchuck Leslie, Lu Ming, Chen Katherine T, Yawetz Sigal, Pacheco Susan, Davenny Katherine, Adeniyi-Jones Samuel, Thomas David L
University of Illinois at Chicago School of Public Health, Chicago, IL 60612, USA.
Clin Infect Dis. 2005 Mar 15;40(6):859-67. doi: 10.1086/428121. Epub 2005 Feb 18.
Despite previous study, it remains unclear whether hepatitis C virus (HCV) coinfection affects the progression of human immunodeficiency virus (HIV) type 1 infection. The Women and Infants Transmission Study provided an opportunity to assess this issue.
Longitudinal data on 652 HIV-1-infected women enrolled in the study before the availability of highly active antiretroviral therapy (HAART; 1989-1995) were analyzed. Random effects models were used to determine whether HCV coinfection was associated with different CD4+ cell percentages and HIV-1 RNA levels over time, and Cox proportional hazards models were used to compare the rates of clinical progression to acquired immunodeficiency syndrome (AIDS) or death.
Of 652 women, 190 (29%) were HCV infected. During follow-up, 19% of women were exposed to HAART. After controlling for indicators of disease progression (CD4+ cell percentages and HIV-1 RNA levels determined closest to the time of delivery in pregnant women), ongoing drug use, receipt of antiretroviral therapy, and other important covariates, no differences were detected in the HIV-1 RNA levels, but the CD4+ cell percentages were slightly higher in HCV-infected women than in HCV-uninfected women. During follow-up, 48 women had progression to a first clinical AIDS-defining illness (ADI), and 26 died with no documented antecedent ADI. In multivariable analyses, HCV-infected participants did not have faster progression to a first class C AIDS-defining event or death (relative hazard, 0.75; 95% confidence interval, 0.37-1.53).
In this cohort, the rate of clinical progression of HIV-1 infection was not greater for HCV-infected women.
尽管之前已有研究,但丙型肝炎病毒(HCV)合并感染是否会影响1型人类免疫缺陷病毒(HIV)感染的进展仍不清楚。母婴传播研究为评估这一问题提供了契机。
分析了652名在高效抗逆转录病毒治疗(HAART;1989 - 1995年)可用之前就参与该研究的HIV - 1感染女性的纵向数据。使用随机效应模型来确定HCV合并感染是否随时间与不同的CD4 +细胞百分比和HIV - 1 RNA水平相关,并且使用Cox比例风险模型来比较获得性免疫缺陷综合征(AIDS)或死亡的临床进展率。
652名女性中,190名(29%)感染了HCV。在随访期间,19%的女性接受了HAART。在控制了疾病进展指标(孕妇分娩时最接近的时间所测定的CD4 +细胞百分比和HIV - 1 RNA水平)、持续吸毒、接受抗逆转录病毒治疗以及其他重要协变量后,未检测到HIV - 1 RNA水平存在差异,但HCV感染女性的CD4 +细胞百分比略高于未感染HCV的女性。在随访期间,48名女性进展为首次临床艾滋病定义疾病(ADI),26名女性在无记录的先前ADI情况下死亡。在多变量分析中,HCV感染参与者进展为首次C类艾滋病定义事件或死亡的速度并不更快(相对风险,0.75;95%置信区间,0.37 - 1.53)。
在该队列中,HCV感染女性的HIV - 1感染临床进展率并不更高。